—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Immunovant Inc (IMVT) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for IMVT, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 1.33 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How IMVT has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.33 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Immunovant Inc moved 1.33% on average · correlation 0.21 · higher than 95% of US names
  • Beta, last 3 months 1.21 about the same as over the year
  • On the 10 worst bond days −2.61% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −1.56% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against IMVT on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Immunovant Inc

IMVT in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Immunovant is a clinical-stage biotechnology company that develops antibody therapies for autoimmune diseases. Its main candidate blocks the neonatal receptor that recycles antibodies in the body, a mechanism aimed at conditions such as Graves' disease, myasthenia gravis and lupus-related skin disease. It runs no commercial products yet and depends on trial results to advance its pipeline. Based in Durham, North Carolina, it operates as a subsidiary of Roivant Sciences.
Where it sits in the stack
Immunovant carries no seat in Rubin or Halo, our two Closelook indices, so it sits in the healthcare and biotechnology sleeve of our wider universe rather than inside a build-out stack.
Who it is priced against
Closelooknet's peer group has no entry for Immunovant; the comparison the market draws is with Argenx, which develops therapies through the same neonatal Fc receptor pathway.
Why Closelooknet tracks it
It carries a Closelooknet score, but only one module has been scored so far, so the read is still being built; it holds no index seat and no diary quote yet.
What the diary watches
Whether trial results on its antibody candidate shift the chart, which recently sat below its 50-day average but above its 200-day average.

Immunovant Inc (IMVT) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Immunovant Inc (IMVT)?

Immunovant Inc trades as IMVT on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is IMVT in a Closelooknet index?

Not currently — Immunovant Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does IMVT trade against its moving averages?

Pullback inside an uptrend stack: Trades -17.4% vs the 50-day and +1% vs the 200-day average, 29.3% below the 52-week high and +101.3% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Immunovant Inc compare with its peers?

Against its peer group (Biotechnology · US), Immunovant Inc (IMVT) sits 29.3% below its 52-week high, 17.4% below its 50-day average; BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Caris Life Sciences, Inc. Common Stock (CAI) is 18.4% below. Put any of them next to IMVT in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Immunovant Inc trade when bond yields rise?

Over the past year Immunovant Inc had a beta of 1.33 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 95% of US names. On the 10 sessions in which long bonds fell most it moved −2.61% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Immunovant Inc do?

Immunovant is a clinical-stage biotechnology company that develops antibody therapies for autoimmune diseases. Its main candidate blocks the neonatal receptor that recycles antibodies in the body, a mechanism aimed at conditions such as Graves' disease, myasthenia gravis and lupus-related skin disease. It runs no commercial products yet and depends on trial results to advance its pipeline. Closelooknet's peer group has no entry for Immunovant; the comparison the market draws is with Argenx, which develops therapies through the same neonatal Fc receptor pathway.

Where does Immunovant Inc sit in the AI build-out?

Immunovant carries no seat in Rubin or Halo, our two Closelook indices, so it sits in the healthcare and biotechnology sleeve of our wider universe rather than inside a build-out stack. It carries a Closelooknet score, but only one module has been scored so far, so the read is still being built; it holds no index seat and no diary quote yet.

What does this page show?

A live price chart with SMA overlays and drawing tools for IMVT, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.